12 results on '"Choi, Seung Ho"'
Search Results
2. Pretreatment quality of life as a prognostic factor for early survival and functional outcomes in patients with head and neck cancer
- Author
-
Yang, Chan Joo, Roh, Jong-Lyel, Kim, Min-Ju, Lee, Sang-wook, Kim, Sung-Bae, Choi, Seung-Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Published
- 2016
- Full Text
- View/download PDF
3. The impact of skeletal muscle depletion on older adult patients with head and neck cancer undergoing primary surgery.
- Author
-
Jung, Ah. Ra, Roh, Jong-Lyel, Kim, Jae Seung, Choi, Seung-Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Abstract
Sarcopenia may result in negative outcomes in patients with cancer, but its impact on surgical and oncological outcomes in older adult patients with head and neck squamous cell carcinoma (HNSCC) has not been systematically studied. This study evaluated the clinical impact of sarcopenia on postsurgical and oncological outcomes in older adult patients with HNSCC. This is a prospective study of 190 consecutive HNSCC patients aged ≥65 years who underwent curative surgery at a tertiary referral hospital. Sarcopenia was determined from measurement of the cross-sectional area of skeletal muscles at the level of the third lumbar vertebra on pretreatment images of whole body
18 F-fluorodeoxyglucose positron emission tomography/computed tomography. Primary outcomes were early complications and overall survival. Factors of early complications and readmission were identified using binary logistic regression analyses, and factors of overall survival and disease-free survival were identified using univariate and multivariate Cox proportional hazards regression analyses. Pretreatment sarcopenia were found in 64 (33.7%) patients. In multivariate analysis, sarcopenia and N classification were significantly associated with early complications, while sarcopenia and T classification were associated with readmission. Independent factors of overall survival outcomes were age, sarcopenia, and extranodal extension (all P <.005). Sarcopenia was also an independent factor predictive of disease-free survival outcome (P <.001). Sarcopenia was associated with a 3.2-fold increase in the early complication rate and 4.5-fold increase in mortality in older adult surgical patients with HNSCC. Sarcopenia may predict early complications and survival after curative surgery in older adult patients with HNSCC. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
4. Pretreatment albumin level predicts survival in head and neck squamous cell carcinoma.
- Author
-
Lim, Won Sub, Roh, Jong‐Lyel, Kim, Sung‐Bae, Choi, Seung‐Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Abstract
Objectives/hypothesis: Poor nutritional status in patients with head and neck squamous cell carcinoma (HNSCC) is associated with tumor progression and survival. This study examined the prognostic value of nutritional and hematological markers in patients with HNSCC who received definitive treatments.Study Design: A prospective observational cohort study.Methods: This study included 338 consecutive patients who underwent surgery and/or radiotherapy/chemoradiotherapy for treatment-naïve HNSCC. Body weight and nutritional and hematological parameters were regularly measured before and after treatment. Univariate and multivariate analyses using Cox proportional hazards models were performed to identify factors associated with disease-free survival (DFS), cancer-specific survival (CSS), and overall survival (OS).Results: Body weight, serum total protein and albumin levels, and hematological variables significantly decreased after treatment. Univariate analyses illustrated that age, tumor site, T and N classifications, overall stage, pretreatment serum albumin (<3.5 g/dL) and hemoglobin (<12 g/dL) levels, and neutrophil-lymphocyte ratio were significantly associated with DFS, CSS, and OS (all P < .05). Multivariate analyses identified age, tumor site, N classification, and pretreatment albumin levels as independent predictors of DFS, CSS, and OS (all P < .05). Patients with low serum albumin levels prior to treatment experienced approximately sixfold increases in the risks of tumor progression and cancer-specific and overall mortality compared to the findings in their counterparts.Conclusions: Our results suggest that pretreatment serum albumin levels predict DFS, CSS, and OS in patients who received definitive treatment for HNSCC. These findings might help to predict treatment outcome and guide nutritional intervention in patients with HNSCC.Level Of Evidence: 2b. Laryngoscope, 127:E437-E442, 2017. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
5. Pretreatment Dysphagia Inventory and videofluorographic swallowing study as prognostic indicators of early survival outcomes in head and neck cancer.
- Author
-
Yang, Chan Joo, Roh, Jong‐Lyel, Choi, Kyoung Hyo, Kim, Min‐Ju, Choi, Seung‐Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Subjects
HEAD & neck cancer ,DEGLUTITION disorders ,VIDEOFLUOROSCOPY ,DEGLUTITION ,SQUAMOUS cell carcinoma ,QUESTIONNAIRES ,LYMPH nodes - Abstract
BACKGROUND The prognostic role of swallowing-related, pretreatment subjective and objective findings has not been investigated in detail. The authors evaluated the association between pretreatment MD Anderson Dysphagia Inventory (MDADI) or videofluorographic swallowing study (VFSS) results and standard outcomes, including early recurrence and survival, in patients with treatment-naïve head and neck squamous cell carcinoma (HNSCC). METHODS Patients with HNSCC (n = 191) who received treatment at the authors' institution and were examined by self-administered MDADI questionnaires and VFSS were prospectively enrolled. MDADI and VFSS findings were analyzed in correlation with clinicopathologic variables, and factors that predicted 2-year disease-free survival (DFS) and overall survival (OS) were identified using a Cox proportional-hazards regression model. RESULTS The 2-year OS and DFS rates were 80.1% and 77.5%, respectively. Clinical tumor (T) and lymph node (N) classifications, overall TNM stage, sex, tumor site, and educational level were significantly associated with specific MDADI subdomains, whereas Karnofsky performance score was significantly associated with all MDADI subdomains. After controlling for clinical factors, total scores, global assessment scores, and emotional and physical MDADI subscores were significantly predictive of 2-year OS and DFS ( P < .05 for each). VFSS findings were not significantly associated with survival ( P > .05). CONCLUSIONS The current results provide evidence of the prognostic role of the MDADI in predicting early survival outcomes in patients with HNSCC. The MDADI may be a practical and noninvasive method for the identification of patients at risk who would benefit from close follow-up. Cancer 2015;121:1588-1598. © 2015 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Effect of Metformin on Progression of Head and Neck Cancers, Occurrence of Second Primary Cancers, and Cause-Specific Survival.
- Author
-
Kwon, Minsu, Roh, Jong‐Lyel, Song, Jihyun, Lee, Sang‐Wook, Kim, Sung‐Bae, Choi, Seung‐Ho, and Nam, Soon Yuhl
- Subjects
METFORMIN ,SECONDARY primary cancer ,CHI-squared test ,CONFIDENCE intervals ,DIABETES ,FISHER exact test ,HEAD tumors ,NECK tumors ,RESEARCH funding ,STATISTICS ,SURVIVAL analysis (Biometry) ,SURVIVAL ,DATA analysis ,CONTINUING education units ,RETROSPECTIVE studies ,DATA analysis software ,DESCRIPTIVE statistics ,KRUSKAL-Wallis Test ,DISEASE complications ,DIAGNOSIS ,TUMOR risk factors - Abstract
Background. This study aimed to investigate the effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival. Methods. This study analyzed a retrospective cohort of 1,151 consecutive patients with head and neck squamous cell carcinoma who were treated at our hospital. Patients were divided into three groups: nondiabetic, nonmetformin, and metformin. Clinical characteristics, recurrence of index head and neck cancer, occurrence of second primary cancer, and survival were compared among the different groups. Results. Of 1,151 patients, 99 (8.6%) were included in the metformin group, 79 (6.8%) were in the nonmetformin group, and 973 (84.5%) were in the nondiabetic group. Diabetic status and metformin exposure had no significant impact on index head and neck cancer recurrence or second primary cancer development (p > .2). The nonmetformin group showed relatively lower overall (p = .017) and cancer-specific (p = .054) survival rates than the other groups in univariate analyses, but these results were not confirmed in multivariate analyses. Conclusion. Metformin use did not show beneficial effects on index tumor progression, second primary cancer occurrence, and cause-specific survival in patients with head and neck cancer compared with nonmetformin users and nondiabetic patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. Second Cancer Incidence, Risk Factor, and Specific Mortality in Head and Neck Squamous Cell Carcinoma.
- Author
-
Lee, Dong Hwan, Roh, Jong-Lyel, Baek, Seunghee, Jung, Jae Hoon, Choi, Seung-Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Published
- 2013
- Full Text
- View/download PDF
8. Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer.
- Author
-
Jung, Ah Ra, Roh, Jong-Lyel, Kim, Jae Seung, Choi, Seung-Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Subjects
- *
MUSCLE mass , *HEAD & neck cancer , *SKELETAL muscle , *CANCER prognosis , *COMPUTED tomography , *PREDICTION models - Abstract
Objectives: Diminished skeletal muscle mass (SMM) is a reliable marker of poor survival outcomes in patients with cancer. SMM or body composition is generally assessed at the third lumbar vertebra (L3) by abdominal computed tomography (CT) scans, not routinely evaluated in patients with head and neck squamous cell carcinoma (HNSCC). Therefore, we evaluated the effectiveness of head and neck CT images to assess SMM in patients with HNSCC for predicting their overall survival.Materials and Methods: SMM was assessed in 305 consecutive patients with stage III-IV HNSCC by measuring the cross-sectional area (CSA) at the third lumbar and cervical (C3) vertebrae levels. A formula for predicting the L3 SMM was established using linear regression analysis obtained from C3 CSA and other clinical factors. The actual SMM CSAs measured at L3 level and those obtained from the prediction model were compared using correlation analysis. The predictive power of our formula for estimating overall survival was compared using C-index.Results: Median SMM CSAs at the L3 and C3 levels were 174.5 cm2 and 56.3 cm2, respectively, and were not strongly correlated (adjusted R2 = 0.421). Prediction model 2 included the strongest predictive factors including sex, age, weight, and C3 SMM CSA, and significantly increased the L3 SMM correlation power (adjusted R2 = 0.721). The C-index of the prediction model was 0.713 (95% confidence interval 0.692-0.747).Conclusions: Head and neck CT imaging might be useful to estimate L3 SMM and predict overall survival in HNSCC patients. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
9. Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer.
- Author
-
Jung, Ah Ra, Roh, Jong-Lyel, Kim, Jae Seung, Kim, Sung-Bae, Choi, Seung-Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Subjects
- *
CANCER relapse , *HEAD & neck cancer treatment , *CANCER treatment , *ADIPOSE tissues , *BLOOD protein disorders , *BODY composition , *COMPUTED tomography , *DEOXY sugars , *LONGITUDINAL method , *LUMBAR vertebrae , *MULTIVARIATE analysis , *HEAD & neck cancer , *ONCOGENES , *RADIOPHARMACEUTICALS , *SQUAMOUS cell carcinoma , *STATISTICS , *SURVIVAL , *TUMOR classification , *MULTIPLE regression analysis , *BODY mass index , *TREATMENT effectiveness , *SARCOPENIA , *PROPORTIONAL hazards models , *LEAN body mass , *SKELETAL muscle , *PROGNOSIS , *CANCER risk factors ,MORTALITY risk factors - Abstract
Head and neck squamous cell carcinoma (HNSCC) is commonly associated with a high risk of malnutrition and sarcopenia, related to adverse clinical outcomes. This study evaluated the prognostic values of body composition on recurrence and survival in patients with advanced-stage HNSCC. This study prospectively enrolled 258 consecutive patients with definitive treatments for advanced-stage HNSCC. For the determination of sarcopenia, the cross-sectional area of the skeletal muscles (SMs) was measured at the level of the third lumbar vertebra on the computed tomography images of whole-body 18F-fluorodeoxyglucose positron-emission tomography/computed tomography before and after treatments. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify the prognostic factors of disease-free survival (DFS) and overall survival (OS). Pretreatment and post-treatment diminished SM masses (sarcopenia) were found in 17 (6.6%) and 32 (12.4%) of 258 included patients, respectively. All values of body composition, SM index, visceral fat area, lean body mass, fat mass and body mass index significantly decreased after treatment (all P < 0.05). Multivariable analyses showed that age, Charlson comorbidity index, pretreatment and post-treatment sarcopenia, pretreatment hypoalbuminaemia, p16 status and tumour site remained the independent variables predictive of DFS and OS outcomes (all P < 0.05). Patients with sarcopenia before or after treatment had about threefold increased risk of overall recurrence or death. Diminished SM mass may predict recurrence and survival after definitive treatments in patients with advanced-stage HNSCC. • Skeletal muscle mass was measured from computed tomography images at L3 before and after treatment. • Pretreatment and post-treatment sarcopenia were found in 6.6% and 12.4%, respectively. • Most body composition parameters significantly decreased after treatment. • Sarcopenia is the independent risk factor for disease-free and overall survival after treatment. • Sarcopenia was associated with about threefold increased risk of overall recurrence or death. Condensed Abstract : This study evaluated the prognostic values of body composition on recurrence and survival in 258 patients with advanced-stage head and neck squamous cell carcinoma. Sarcopenia was the independent risk factor for poorer disease-free and overall survival outcomes after definitive treatments, showing about threefold increased risk of overall recurrence or death. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma.
- Author
-
Park, Marn Joon, Roh, Jong-Lyel, Kim, Sung-Bae, Choi, Seung-Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Subjects
- *
CANCER treatment , *SQUAMOUS cell carcinoma , *HEAD tumors , *NECK tumors , *BIOMARKERS , *BLOOD cell count , *BLOOD protein disorders , *C-reactive protein , *LONGITUDINAL method , *MULTIVARIATE analysis , *STATISTICS , *SURVIVAL , *TIME , *TUMOR classification , *COMORBIDITY , *TREATMENT effectiveness , *PROPORTIONAL hazards models , *PROGNOSIS , *TUMOR treatment - Abstract
Background Circulating biomarker (CB) is a convenient, emerging predictive tool for treatment response and outcomes in human cancers. Therefore, we examined the prognostic value of pre-treatment and early post-treatment CBs and their summated scores in patients with head and neck squamous cell carcinoma (HNSCC). Methods This study prospectively included 310 consecutive patients who underwent definitive treatment for previously untreated advanced-stage HNSCC between 2010 and 2015. The CB score was determined by complete blood counts (CBCs) and blood chemistry before and 2 months after the treatment, and the number of abnormal CB was counted from 0 to 10. Univariate and multivariate analyses with Cox proportional hazards models were used to find factors associated with disease-free survival (DFS) and overall survival (OS). Results Most CBC profiles were significantly changed at 2-months post-treatment compared with those at pre-treatment. Univariate analyses showed that hypoalbuminemia, leucocytosis, C-reactive protein, high CB scores (≥6), age, performance status and comorbidity and tumour site were significantly associated with DFS and OS (all P < 0.05). Both pre- and post-treatment CB scores were independent factors predictive of DFS and OS outcomes in the multivariate analyses ( P < 0.05). High CB scores at pre-treatment were associated with 7–10-fold increased risk of unfavourable DFS and OS outcomes, and those at 2-months post-treatment were associated with 2 to 4-fold increased risk of poor survival outcomes (all P < 0.05). Conclusions CB scores at pre-treatment and early post-treatment are useful for predicting survival outcomes in patients with advanced-stage HNSCC. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. 18F-FDG PET/CT surveillance for the detection of recurrence in patients with head and neck cancer.
- Author
-
Kim, Shin-Ae, Roh, Jong-Lyel, Kim, Jae Seung, Lee, Jeong Hyun, Lee, Sang Hoon, Choi, Seung-Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Subjects
- *
CANCER relapse , *EVALUATION of diagnostic imaging , *NECK tumors , *COMBINED modality therapy , *COMPUTED tomography , *HEAD tumors , *PROBABILITY theory , *SQUAMOUS cell carcinoma , *SURVIVAL analysis (Biometry) , *POSITRON emission tomography , *LOGISTIC regression analysis , *DATA analysis , *PROPORTIONAL hazards models , *RECEIVER operating characteristic curves , *SURGERY , *DIAGNOSIS - Abstract
Background Posttreatment detection of recurrence may lead to salvage treatment and prognostic prediction in patients with head and neck squamous cell carcinoma (HNSCC). We evaluated the diagnostic and prognostic values of 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET)/computed tomography (CT) after definitive treatment of HNSCC. Methods This prospective study included 278 consecutive patients who underwent curative surgery ( n = 143, 51.4%) or definitive radiotherapy/chemoradiotherapy ( n = 135, 48.6%) for previously untreated HNSCC. The patients were regularly followed up and evaluated by 18 F-FDG PET/CT, head and neck CT/magnetic resonance imaging (MRI), and chest CT at regular intervals after treatment. The imaging interpretations were compared with the histological results for recurrence. Receiver operating characteristics curves analysis, McNemar's test and logistic regression using generalised estimating equations were used to compare the diagnostic accuracy of 18 F-FDG PET/CT and standard imaging of CT/MRI or chest CT, and a Cox proportional hazards model was used to assess the prognostic value of PET/CT. Results During a median follow-up of 44 months (range, 24–62 months), 73 patients (26.3%) had recurrence or persistent diseases. The area under curves for 18 F-FDG PET/CT and CT/MRI were 0.975 (0.964–0.992) and 0.789 (0.713–0.874), respectively ( P < 0.001). 18 F-FDG PET/CT detected 65 of 66 recurrences (98.5%) not suggested by physical examination and endoscopy. Positive findings on 18 F-FDG PET/CT scans were independent predictors of poorer cancer-specific and overall survival outcomes ( P < 0.01). Conclusions Posttreatment 18 F-FDG PET/CT surveillance helps to properly detect recurrence and to predict the survival following treatment of HNSCC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
12. Impact of 18F-FDG PET/CT staging on management and prognostic stratification in head and neck squamous cell carcinoma: A prospective observational study.
- Author
-
Ryu, In Sun, Roh, Jong-Lyel, Kim, Jae Seung, Lee, Jeong Hyun, Cho, Kyung-Ja, Choi, Seung-Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Subjects
- *
DEOXY sugars , *HEAD tumors , *LONGITUDINAL method , *METASTASIS , *NECK tumors , *RADIOPHARMACEUTICALS , *SURVIVAL , *POSITRON emission tomography , *TUMOR classification , *PROGNOSIS - Abstract
Background Accurate assessment of the extent of cancer is essential for appropriate treatment planning and outcome prediction. This study prospectively evaluated whether adding 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET)/computed tomography (CT) to the routine initial staging practice in head and neck squamous cell carcinoma (HNSCC) improved management and prognosis. Methods All consecutive patients with newly diagnosed HNSCC who presented in October 2010 – December 2012 underwent conventional workups (CWU) followed by PET/CT. The clinical stage and management plans before and after PET/CT were compared. PET/CT was deemed to have no/low, moderate, and high impact on management planning depending on whether PET/CT changed the treatment modality or goal. The appropriateness of PET/CT staging and management impact was confirmed by histopathology and clinical follow-up, and its association with survival was analysed. Findings Of the 248 patients, PET/CT changed the Tumour Node Metastasis (TNM) classification in 79 (31.9%). In the patients with discordant staging, PET/CT staging was significantly more sensitive and accurate than CWU staging (both P < 0.001). PET/CT had high or moderate impact on management in 39 (15.7%) patients. Patients with PET/CT upstaged disease had significantly worse progression-free survival (PFS) and overall survival (OS) than patients with no CWU-stage changes (3-year PFS = 56.8% versus 74.5%, P = 0.043; 3-year OS = 61.3% versus 85.3%, P = 0.006). Multivariate analyses revealed that PET/CT staging and second primary cancer were independent predictive factors for both PFS and OS ( P < 0.05, each). Interpretations 18 F-FDG PET/CT added important staging information that improved management and prognostic stratification in HNSCC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.